AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Phase 2 Completed 46 enrolled Eastern Cooperative Oncology Group National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: AMG 706 and octreotide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well AMG 706 and octreotide work in treating patients with low-grade neuroendocrine tumors.

Timeline

Start: 2008-11-07
Primary completion: 2014-10
Completion: 2015-04

Publications

Lubner S, Feng Y, Mulcahy M, O'Dwyer P, Giang GY, Hinshaw JL, Deming D, Klein L, Teitelbaum U, Payne J, Engstrom P, Stella P, Meropol N, Benson A. E4206: AMG 706 and Octreotide in Patients with Low-Grade Neuroendocrine Tumors. Oncologist. 2018 Sep;23(9):1006-e104. doi: 10.1634/theoncologist.2018-0294. Epub 2018 May 31.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	motesanib	Small molecule	125 mg	Oral
Background	Octreotide	Peptide	30 mg	Intramuscular

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Summary

Timeline

Publications

Drugs

Indications